PCS
RNTX

Personal CFO Solutions’s Rein Therapeutics RNTX Stock Holding History

Personal CFO Solutions’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,525
Closed -$31K – 524
2021
Q3 		$31K Sell
1,525
-150
-9% -$3.29K 0.01% 446
2021
Q2 		$42K Hold
1,675
– – 0.01% 433
2021
Q1 		$48K Hold
1,675
– – 0.01% 402
2020
Q4 		$35K Hold
1,675
– – 0.01% 372
2020
Q3 		$0 Sell
1,675
-694
-29% -$16.3K ﹤0.01% 342
2020
Q2 		$56K Buy
2,369
+1,219
+106% +$19.9K 0.02% 303
2020
Q1 		$8K Sell
1,150
-700
-38% -$8.43K ﹤0.01% 275
2019
Q4 		$21K Buy
+1,850
New +$18.3K 0.01% 343

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Personal CFO Solutions's RNTX Position: Q4 2021 in Review

Personal CFO Solutions sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 1,525 shares — an estimated $31K sold.

Personal CFO Solutions first reported a position in RNTX in Q4 2019 and held it in 8 quarters. The position peaked at $56K in Q2 2020. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Personal CFO Solutions reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Personal CFO Solutions sold 1,525 Rein Therapeutics shares in Q4 2021, an estimated $31K.
  • Personal CFO Solutions first reported a position in Rein Therapeutics in Q4 2019 and held it in 8 quarters.
  • Personal CFO Solutions's Rein Therapeutics position peaked at $56K in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on Personal CFO Solutions's 13F filing for Q4 2021, filed 11 Feb 2022.